Rune Labs Closes $5M Seed Round
Summary
Able to work with industry leading systems from Medtronic, Abbott and others as well as mobile health apps and devices like Apple Watch, and fully HIPAA compliant, Rune Labs can enhance precision therapy delivery to patients to further personalize neuromodulation to better control their symptoms. “This round of funding, following closely on last year’s, continues to validate our approach, technology and strategy,” said Brian Pepin, founder and CEO, Rune Labs. Rune Labs also announced an agreement to collaborate on research for University of Minnesota’s upcoming OCD Adaptive DBS studies, under Alik Widge, MD, Ph.D., Assistant Professor, Department of Psychiatry at UM’s Medical School. "The Rune Labs platform has made communication between data acquired from patients implanted at Mount Sinai in New York with the analytic team at Georgia Tech nearly effortless and has proved essential to visualize the data and easily check data quality," said Helen S. Mayberg, M.D., Professor of Neurology, Neurosurgery, Psychiatry, and Neuroscience, and Founding Director of the Nash Family Center for Advanced Circuit Therapeutics at the Icahn School of Medicine at Mount Sinai. With their software, we can view patient state and algorithm performance in near real time and make decisions regarding adaptive DBS parameters, which we then update remotely,” said Roee Gilron, Ph.D., a researcher at the UCSF Weill Institute of Neurosciences and a member of Rune Labs’ scientific advisory board.
Funding
Review available funding amount, funding date, investors, and linked company information related to Rune Labs Closes $5M Seed Round in the interactive ISVWorld profile.